Targets targeted by giritinib in the treatment of leukemia

Gilitinib (Gilteritinib) is a targeted therapy drug mainly used to treat FLT3 (Fms-like tyrosine kinase 3) mutation-positive acute myeloid leukemia (AML). Its mechanism of action targets the FLT3 receptor kinase, which is one of the most common mutations in AML.

Under normal circumstances, FLT3 receptor kinase transmits signals for cell growth and differentiation by binding to its ligand, thereby maintaining the normal functions of cells. However, in some AML patients, the FLT3 gene is mutated, resulting in abnormal activation of the FLT3 receptor kinase. This abnormal activation can lead to excessive proliferation and survival of leukemia cells, thus promoting the development and progression of AML.

Giritinib, as an FLT3 receptor kinase inhibitor, can highly selectively bind and inhibit the activity of FLT3 receptor kinase. By inhibiting the abnormal activation of FLT3 receptor kinase, giritinib can block the proliferation and survival of leukemia cells, thereby slowing the progression of the disease.

In addition to treating FLT3 mutation-positive AML, giritinib has also been studied for other FLT3 related hematological tumors, such as FLT3Mutation-positive acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).

In general, as a targeted therapy drug, giritinib mainly targets theFLT3 receptor kinase. By inhibiting the activity of this kinase, it can effectively controlFLT3Mutation-positiveAML provides patients with a new treatment option.